Discontinuation syndrome in dysthymic patients treated with selective serotonin reuptake inhibitors: A clinical investigation

CNS Drugs

Volumn 16, Issue 4, 2002, Pages 273-283

  Bogetto, Filippo ^a   Bellino, Silvio ^a   Revello, Raffaele Bonatto ^a   Patria, Luca ^a  

^a UNIVERSITY OF TURIN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOXETINE; PAROXETINE; SEROTONIN UPTAKE INHIBITOR;

ADULT; ARTICLE; CLINICAL FEATURE; CLINICAL PRACTICE; CONTROLLED STUDY; DISEASE SEVERITY; DRUG WITHDRAWAL; DYSTHYMIA; FEMALE; GENDER; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE REGRESSION; ONSET AGE; OUTPATIENT CARE; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; RISK FACTOR; WITHDRAWAL SYNDROME;

EID: 0036245708     PISSN: 11727047     EISSN: None     Source Type: Journal    
DOI: 10.2165/00023210-200216040-00006     Document Type: Article

References (46)

1. Discontinuation symptoms after treatment with serotonin reuptake inhibitor: A literature review
2. Tofranil treatment of endogenous depressions
3. Withdrawal symptoms following discontinuation of imipramine therapy
4. Recurrence of depression after discontinuation of amitryptiline
5. Antidepressant withdrawal phenomena
6. Rebound reactions due to clomipramine
7. Tranylcypromine withdrawal phenomena
8. Extrapyramidal symptoms upon discontinuation of fluoxetine
9. The abrupt discontinuation of fluvoxamine in patients with panic disorder
10. Is there a serotonergic withdrawal syndrome?
11. Physical symptoms associated with paroxetine discontinuation
12. Medication withdrawal symptoms in OCD patients treated with paroxetine
13. Severe psychiatric symptoms associated with paroxetine withdrawal
14. Fluoxetine withdrawal?
15. Withdrawal syndromes after paroxetine and sertraline discontinuation
16. Shock-like sensations after discontinuation of selective serotonin reuptake inhibitors
17. Reversible delirium after discontinuation of fluoxetine
18. Paroxetine induced withdrawal effects
19. Discontinuation reactions following sertraline
20. Paroxetine withdrawal syndrome
21. Fluoxetine withdrawal symptoms
22. Serotonin reuptake inhibitor withdrawal
23. Antidepressant withdrawal syndrome: Recognition, prevention and management
24. More cases of paroxetine withdrawal syndrome
25. A comparison of the post-marketing safety of four selective serotonin reuptake inhibitors including reinvestigation of symptoms occurring on withdrawal
26. Withdrawal reactions with selective serotonin reuptake inhibitors as reported to the WHO system
27. Antidepressant discontinuation syndrome: Clinical relevance, prevention and management
28. Antidepressant discontinuation: A review of literature
29. Physicians' knowledge of antidepressant withdrawal effects: A survey
30. Serotonin reuptake inhibitor discontinuation syndrome: A hypothetical definition
31. Paroxetine in the treatment of panic disorder: A randomised, double-blind, placebo-controlled study
32. Serotonin reuptake inhibitor discontinuation syndrome: A randomized clinical trial
33. Safety of abrupt discontinuation of fluoxetine: A randomized, placebo-controlled study
34. Abrupt and brief discontinuation of antidepressant treatment effects on cognitive function and psychomotor performance
35. An assessment of selective serotonin reuptake inhibitor discontinuation symptoms with citalopram
36. Interruption of selective serotonin reuptake inhibitor treatment
37. Discontinuation syndromes with selective serotonin reuptake inhibitors: Are there clinically relevant differences?
38. A rating scale for depression
39. Development of a rating scale for primary depressive illness
40. A new depression scale designed to be sensitive to change
41. New antidepressants and the discontinuation syndrome
42. Selective serotonin reuptake inhibitors discontinuation syndrome: Proposed diagnostic criteria
43. Potential withdrawal syndrome associated with SSRI discontinuation
44. Clinical management of antidepressant discontinuation
45. Potential sensitising effects of antidepressant drugs on depression